Quantedge Capital Pte Ltd increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 295.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,800 shares of the company’s stock after acquiring an additional 70,800 shares during the quarter. Harmony Biosciences comprises 0.4% of Quantedge Capital Pte Ltd’s portfolio, making the stock its 15th biggest holding. Quantedge Capital Pte Ltd’s holdings in Harmony Biosciences were worth $3,722,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC increased its stake in Harmony Biosciences by 166.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $32,000 after acquiring an additional 510 shares during the period. Nykredit A S bought a new stake in shares of Harmony Biosciences during the second quarter worth about $33,000. Signature Equity Partners LLC bought a new position in shares of Harmony Biosciences during the third quarter valued at $37,000. Hantz Financial Services Inc. grew its position in shares of Harmony Biosciences by 32.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,401 shares of the company’s stock valued at $55,000 after buying an additional 345 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in Harmony Biosciences during the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 86.23% of the company’s stock.
Harmony Biosciences Price Performance
Shares of NASDAQ HRMY opened at $32.96 on Tuesday. The stock’s 50-day simple moving average is $38.46 and its two-hundred day simple moving average is $34.60. The firm has a market capitalization of $1.94 billion, a P/E ratio of 11.19, a P/E/G ratio of 0.36 and a beta of 1.00. The company has a quick ratio of 3.42, a current ratio of 3.44 and a debt-to-equity ratio of 0.12. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.90 and a twelve month high of $43.49.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.28). The company had revenue of $268.92 million for the quarter, compared to the consensus estimate of $272.05 million. Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.08 earnings per share. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.55 EPS for the current fiscal year.
Insiders Place Their Bets
In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the completion of the sale, the insider directly owned 13,115 shares in the company, valued at $564,600.75. This represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 72,406 shares of company stock valued at $3,108,520 over the last ninety days. Insiders own 11.00% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently issued reports on HRMY shares. Mizuho set a $49.00 target price on shares of Harmony Biosciences in a report on Thursday, October 29th. Truist Financial lifted their price objective on shares of Harmony Biosciences from $29.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. UBS Group reiterated a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a research note on Wednesday, August 5th. Wolfe Research began coverage on Harmony Biosciences in a research report on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Monday, October 19th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $48.00.
Check Out Our Latest Research Report on Harmony Biosciences
Harmony Biosciences Profile
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Read More
- Five stocks we like better than Harmony Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
